Older Antihypertensives As Good As The New

23 July 1997

Results of a large comparative study suggest that newerantihypertensives such as calcium channel blockers and ACE inhibitors are no more effective than their predecessors, diuretics and beta blockers, for the treatment of mild-to-moderate hypertension (British Medical Journal July 19).

The 900 patients in the study were randomized to treatment with hydrochlorothiazide, atenolol, nitrendipine or enalapril and evaluated over one year. Based on measurements of potency and tolerability, the researchers concluded that "atenolol was the most effective drug, while nitrendipine showed the highest drop-out rate." There was no evidence that the newer drugs had superior antihypertensive effectiveness or superior tolerability.

New Studies Called For The team suggested that as the newer drugs are widely accepted as first-line agents, there is a need for research to confirm that they reduce morbidity and mortality, as has been demonstrated with diuretics and beta blockers.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight